2023
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu Z, Brooks M, Irvin S, Jordan S, Aben K, Anton-Culver H, Bandera E, Beckmann M, Berchuck A, Brooks-Wilson A, Chang-Claude J, Cook L, Cramer D, Cushing-Haugen K, Doherty J, Ekici A, Fasching P, Fortner R, Gayther S, Gentry-Maharaj A, Giles G, Goode E, Goodman M, Group A, Harris H, Hein A, Kaaks R, Kiemeney L, Köbel M, Kotsopoulos J, Kotsopoulos J, Le N, Lee A, Matsuo K, McGuire V, McLaughlin J, Menon U, Milne R, Moysich K, Pearce C, Pike M, Qin B, Ramus S, Riggan M, Rothstein J, Schildkraut J, Sieh W, Sutphen R, Terry K, Thompson P, Titus L, van Altena A, White E, Whittemore A, Wu A, Zheng W, Ziogas A, Taylor S, Tang L, Songer T, Wentzensen N, Webb P, Risch H, Modugno F. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. Journal Of The National Cancer Institute 2023, 115: 539-551. PMID: 36688720, PMCID: PMC10165492, DOI: 10.1093/jnci/djad011.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOral contraceptive useClear cell histotypeOvulatory yearsOvulation suppressionOdds ratioOvarian cancerContraceptive useNonmucinous epithelial ovarian cancerConfidence intervalsConsistent protective effectCase patientsMucinous tumorsPooled analysisProtective effectEOC riskControl participantsHistotypeCancerOvulationAssociationRegression modelsRiskYearsBeta coefficients
2019
Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study
Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ, Group A, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Lindström S, Terry K. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal Of Epidemiology 2019, 48: 822-830. PMID: 31211375, PMCID: PMC6659359, DOI: 10.1093/ije/dyz113.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvarian cancer riskOvarian Cancer Association ConsortiumSelf-reported polycystic ovary syndromeInvasive ovarian cancerOvarian cancerCancer riskOvary syndromeInverse associationOral contraceptive useReproductive-aged womenBody mass indexSingle nucleotide polymorphismsStrong inverse associationComplex endocrine disorderObservational study resultsMendelian randomization studyEuropean ancestry womenEndometrioid tumorsMass indexDecreased riskEndocrine disordersSpecific histotypesContraceptive useAged women
2014
Risk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2014, 24: 664-669. PMID: 24755492, DOI: 10.1097/igc.0000000000000134.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCanadaCystadenocarcinoma, SerousDNA, NeoplasmEndometrial NeoplasmsFemaleGenetic Predisposition to DiseaseHumansMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedMutationNeoplasm StagingOvarian NeoplasmsPrognosisRisk FactorsSyndromeUnited StatesConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexTubal ligationRisk factorsBRCA2 mutationsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersCases of cancerMSI-high tumorsBRCA2 mutation status
2013
Risk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2013, 23: 1010. PMID: 23748177, PMCID: PMC3740723, DOI: 10.1097/igc.0b013e31829a5527.Peer-Reviewed Original ResearchConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexHistologic findingsTubal ligationRisk factorsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsDifferent histologic findingsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersMSI-high tumorsBRCA2 mutation status
2003
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)
Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, Wheeler JE, Wonderlick A, Fishman D, Karlan B, Risch H, Cramer DW, Dube MP, Narod SA. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes & Control 2003, 14: 439-446. PMID: 12946038, DOI: 10.1023/a:1024932427503.Peer-Reviewed Original ResearchConceptsBRCA1 carriersOC useTubal ligationOvarian cancerReproductive factorsInvasive epithelial ovarian cancerFounder mutationOral contraceptive useHistory of breastfeedingEpithelial ovarian cancerOvarian cancer casesOvarian cancer riskBRCA1 founder mutationsBRCA2 mutation carriersAshkenazi founder mutationsCase-only studyNulliparous womenGynecologic surgeryBRCA1/2 carriersRisk factorsBRCA2 mutationsCancer casesLive birthsBRCA1/2 mutationsContraceptive use
2001
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
Runnebaum I, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin A, Risch H, Garber J, Lerman C, Olopade O, Foulkes W, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé M, Kieback D, Narod S. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics And Genomics 2001, 11: 635-638. PMID: 11668223, DOI: 10.1097/00008571-200110000-00010.Peer-Reviewed Original ResearchConceptsPROGINS alleleOvarian cancerOral contraceptivesBRCA2 mutationsCarriers of BRCA1Oral contraceptive useOvarian cancer riskHereditary ovarian cancerBRCA2 mutation carriersOral contraception useForms of cancerYear of birthPrior diagnosisBRCA2 carriersProgesterone receptorBreast cancerMutation carriersContraceptive useCancer riskContraception useHereditary breastDisease statusPast exposureCancerBRCA1 mutations
2000
Multiple Births and Risk of Epithelial Ovarian Cancer
Whiteman D, Murphy M, Cook L, Cramer D, Hartge P, Marchbanks P, Nasca P, Ness R, Purdie D, Risch H. Multiple Births and Risk of Epithelial Ovarian Cancer. Journal Of The National Cancer Institute 2000, 92: 1172-1177. PMID: 10904091, DOI: 10.1093/jnci/92.14.1172.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerParous womenOvarian cancerMultiple birthsCase patientsOdds ratioMultivariable logistic regression analysisNonmucinous ovarian cancerOral contraceptive useSummary odds ratiosLogistic regression analysisNonmucinous tumorsMucinous tumorsHistologic typeTumor histologyControl womenInvasive tumorsRelative riskReproductive factorsContraceptive useOvarian carcinogenesisLower riskCancerAvailable evidenceTumors
1996
Differences in Risk Factors for Epithelial Ovarian Cancer by Histologic Type
Risch H, Marrett L, Jain M, Howe G. Differences in Risk Factors for Epithelial Ovarian Cancer by Histologic Type. American Journal Of Epidemiology 1996, 144: 363-372. PMID: 8712193, DOI: 10.1093/oxfordjournals.aje.a008937.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerMucinous tumorsNonmucinous tumorsOvarian cancerHistologic typeOdds ratioPrimary epithelial ovarian cancerUnconditional logistic regression methodsInvasive serous cancerMucinous ovarian tumorsOral contraceptive useFull-term pregnancyRisk factor associationsCase-control studyOral contraceptivesSerous cancerEndometrioid cancerNoncontraceptive estrogensFat intakeInvasive cancerOvarian tumorsRisk factorsEpithelial tumorsReproductive factorsContraceptive use
1994
Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada)
Risch H, Jain M, Marrett L, Howe G. Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada). Cancer Causes & Control 1994, 5: 540-548. PMID: 7827241, DOI: 10.1007/bf01831382.Peer-Reviewed Original ResearchConceptsOral contraceptive useOvarian cancerContraceptive useLactose intoleranceTotal daily caloric intakeFull-term pregnancyEpithelial ovarian cancerCase-control studyDaily caloric intakeQuantitative diet historyDietary factorsLactose intakeCaloric intakeProtective effectDiet historyAge groupsCancerDaily consumptionIntoleranceIntakeTotal durationIntake valuesPopulation controlsRiskMore evidence